WO2017057891A1 - Composition de prévention du grisonnement des cheveux - Google Patents

Composition de prévention du grisonnement des cheveux Download PDF

Info

Publication number
WO2017057891A1
WO2017057891A1 PCT/KR2016/010825 KR2016010825W WO2017057891A1 WO 2017057891 A1 WO2017057891 A1 WO 2017057891A1 KR 2016010825 W KR2016010825 W KR 2016010825W WO 2017057891 A1 WO2017057891 A1 WO 2017057891A1
Authority
WO
WIPO (PCT)
Prior art keywords
hair
ginsenoside
glc
composition
present
Prior art date
Application number
PCT/KR2016/010825
Other languages
English (en)
Korean (ko)
Inventor
김수나
신승현
김아름
김세현
나용주
Original Assignee
주식회사 아모레퍼시픽
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 아모레퍼시픽 filed Critical 주식회사 아모레퍼시픽
Priority to CN201680057138.2A priority Critical patent/CN108135822A/zh
Priority to JP2018516107A priority patent/JP2018529712A/ja
Priority to KR1020160124524A priority patent/KR102586261B1/ko
Publication of WO2017057891A1 publication Critical patent/WO2017057891A1/fr
Priority to HK18108371.2A priority patent/HK1248569A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair

Definitions

  • the present invention relates to a composition for preventing white hair.
  • Hair and scalp are parts of the body that, like age, develop aging.
  • the amount of melanin in the hair may decrease or white hair phenomenon may occur.
  • Wnt signaling pathway by Wnt protein not only plays a critical role in the formation of human brain and differentiation of neurons, but also inhibits hair growth by the Wnt inhibitor, APCDD1. It is known that there exists (nonpatent literature 1).
  • Wnt inhibitor WIF-1 Wnt inhibitory factor-1
  • Wnt inhibitory factor-1 is known to inhibit melanin synthesis in connection with skin blemishes.
  • the Wnt inhibitor inhibits hair growth
  • the research which promotes hair growth by activating a Wnt signal has been studied.
  • the relationship between Wnt inhibitors and white hair formation is not clearly known, and there is no known substance that inhibits, improves, and prevents white hair.
  • Non-Patent Document 1 Nature 464, 1043-1047, Yutaka Shimomura et al (2010.04.15.)
  • Non-Patent Document 2 Journal of Investigative Dermatology (2013) 133, 191-200, Ji-Young Kim et al (2012.09.06.)
  • the present invention is to provide a composition that can promote the melanin synthesis by reducing the expression of the Wnt inhibitor to prevent white hair phenomenon due to scalp aging.
  • the present invention provides a composition for preventing white hair, comprising ginsenoside represented by the following formula (1) as an active ingredient.
  • R 1 is hydrogen
  • R 2 is -O-glc or -O-glc (2-1) rha
  • R 3 is -glc.
  • composition for preventing white hair contains the ginsenoside as an active ingredient and, when applied to the scalp, reduces the expression of WIF-1, a Wnt inhibitor, to the skin such as the face of the conventionally known WIF-1. Based on melanin suppression mechanisms to improve or activate melanin delivery of hair follicles and hair to prevent white hair phenomenon.
  • Figure 1 shows the relative gene expression of WIF-1 of the age-specific test group according to Test Example 1.
  • Figure 2 WIF- of the untreated group, positive control group, ginsenoside Rb1, ginsenoside Rb2, ginsenoside Rc, ginsenoside Rd, ginsenoside Re and ginsenoside Rg1 treatment group according to Test Example 2 below.
  • the relative gene expression amount of 1 is shown.
  • Figure 3 shows the relative melanin synthesis amount of the untreated group, negative control group, ginsenoside Re and ginsenoside Rg1 treatment group according to Test Example 3 below.
  • the prevention of white hair should be interpreted to include the prevention of white hair phenomenon in which the amount of melanin in the hair is reduced or absent, as well as improvement of the white hair phenomenon which suppresses or stops the already developed white hair phenomenon.
  • composition for preventing white hair according to the present invention contains ginsenoside represented by the following Chemical Formula 1 as an active ingredient.
  • R 1 is hydrogen
  • R 2 is -glc or -glc (2-1) rha
  • R 3 is -glc.
  • ginsenoside refers to glycoside of glycoside isolated from ginseng.
  • the structure of ginsenoside is specifically named ginsenoside Rx, and for ginsenoside Rx, "R” means root (Radix or Root), and "x” is Named in order of o, a, b, c, d, e, f, g and h from bottom to top according to the distance (Rf value) of the spot appearing on Thin Layer Chromatography (TLC) will be.
  • the ginsenoside compound and its structure according to the ginsenoside nomenclature are shown in Table 1 below, the structures are all represented by the formula (1), and only the substituents of R 1 to R 3 in the formula.
  • Ginsenoside Compound Name Substituent of Formula 1 R 1 R 2 R 3 Ginsenoside Rb1 -glc (2-1) glc Hydrogen -glc-glc Ginsenoside Rb2 -glc (2-1) glc Hydrogen -glc-ara (pyr) Ginsenoside Rc -glc (2-1) glc Hydrogen -glc-ara (fur) Ginsenoside Rd -glc (2-1) glc Hydrogen -glc Ginsenoside Re Hydrogen -glc (2-1) rha -glc Ginsenoside Rg1 Hydrogen -glc -glc
  • the ginsenoside of the composition for preventing white hair according to the present invention can be separated from the extract of ginseng, the extract of ginseng may be extracted from the root, stem, leaf or flesh of ginseng, preferably from the root or leaf of ginseng have.
  • the extract of the ginseng is not limited to the present invention by the extraction site.
  • the extract of ginseng may be extracted by filtration and concentrated under reduced pressure with a lower alcohol having a carbon number of 1 to 4 or a mixed solvent thereof, preferably methanol, or a portion of the dried ginseng
  • a lower alcohol having a carbon number of 1 to 4 or a mixed solvent thereof, preferably methanol, or a portion of the dried ginseng The present invention is not limited by the extraction method.
  • the ginsenoside is preferably, by sequentially adding an organic solvent, for example, n-hexane, ethyl acetate, n-butanol, etc. to the extract of the ginseng and purified fractions thereof , Chromatography, for example, silica gel column chromatography, L-20 column chromatography, thin layer chromatography, high performance liquid chromatography The separation can be performed using high performance liquid chromatography), but the present invention is not limited by the separation method.
  • an organic solvent for example, n-hexane, ethyl acetate, n-butanol, etc.
  • Chromatography for example, silica gel column chromatography, L-20 column chromatography, thin layer chromatography, high performance liquid chromatography
  • the separation can be performed using high performance liquid chromatography), but the present invention is not limited by the separation method.
  • glc means ⁇ -D-glucopyranosyl group
  • ara (pyr) means L-arabinopyranosyl
  • ara (fur) means L-arabinofranosyl group.
  • rha means ⁇ -L-rhamnopyranosyl.
  • Panax ginseng ginseng is a perennial herb of the droopaceae family.
  • ginsenosides represented by Formula 1 are ginsenoside Re, ginsenoside Rg1 or a mixture thereof.
  • the ginsenoside represented by Formula 1 is ginsenoside Re, or ginsenoside Rg1.
  • the ginsenoside of Formula 1 is hydrogen, R 2 is -glc, R 3 is -glc is ginsenoside Re.
  • the ginsenoside of Formula 1 is hydrogen, R 2 is -glc (2-1) rha, R 3 is -glc is ginsenoside Rg1.
  • the ginsenoside represented by Formula 1 is ginsenoside Rb1, ginsenoside Rb2, ginsenoside Rc, ginsenoside Rd, ginsenoside Re, ginsenoside Rg1 or these Is a mixture of.
  • the content of ginsenoside is 0.000001 wt% to 10 wt%, preferably 0.0001 wt% to 10 wt% based on the total weight of the composition. If the content of ginsenosad is less than 0.000001% by weight, the anti-white hair activity is insufficient, and if it exceeds 10% by weight, the increase in anti-white hair activity is insufficient.
  • the composition for preventing white hair is to suppress the expression of WIF-1.
  • WIF-1 means a protein that inhibits the Wnt protein.
  • the Wnt protein is a group of lipid-regulated signaling glycoproteins having a length of 350 to 400 amino acids, and serves as a signal transduction in the Wnt signaling pathway, and in humans, Wnt1 and Wnt2.
  • Such proteins include Wnt2B, Wnt3, Wnt3A, Wnt4, Wnt5A, Wnt5B, Wnt6, Wnt7A, Wnt7B, Wnt8A, Wnt8B, Wnt9A, Wnt9B, Wnt10A, Wnt10B, Wnt11, and Wnt16.
  • the anti-hair care composition in the present invention may be formulated as an external composition for skin, particularly a cosmetic composition, and may be formulated containing a cosmetically or dermatologically acceptable medium or base.
  • the compositions of the present invention may be provided in all formulations suitable for topical application, for example, emulsions obtained by dispersing an oil phase in a solution, an aqueous phase, emulsions obtained by dispersing an aqueous phase in an oil phase, suspensions, solids, gels, powders, It may be provided in the form of a paste, foam or aerosol composition. Compositions of such formulations may be prepared according to conventional methods in the art.
  • the present invention provides a use of the topical skin composition containing ginsenoside represented by the formula (1) as an active ingredient in the manufacture of cosmetics for preventing hair loss.
  • the present invention provides a method for preventing white hair, comprising applying to the scalp an external composition for skin containing ginsenosides represented by Chemical Formula 1 as an active ingredient.
  • the composition for preventing white hair is shampoo, conditioner, hair tonic, hair nourishing longevity, hair essence, hair serum scalp treatment, hair treatment, hair conditioner, hair shampoo and hair lotion in the group At least one formulation selected.
  • composition for preventing white hair according to the present invention may further contain appropriate ingredients according to the formulation, which will be described in detail below.
  • it further contains any one or more selected from the group consisting of surfactants, preservatives and viscosity regulators, pH regulators, fragrances, dyes, hair conditioning agents and water.
  • the surfactant is any one or more selected from anionic surfactants, amphoteric surfactants and nonionic surfactants.
  • the anionic surfactant may be alkyl sulfate or alkyl ether sulfate, and specific examples thereof include sodium lauryl sulfate, lauryl ammonium sulfate, lauryl sulfate triethanolamine, polyoxyethylene lauryl sulfate, polyoxyethylene lauryl ammonium sulfate, and the like. Can be mentioned.
  • the amphoteric surfactant may be alkyl betaine or alkyl amidopropyl betaine, specific examples of which are cocodimethyl carboxymethyl betaine, lauryldimethyl carboxymethyl betaine, lauryldimethyl alpha-carboxyethyl betaine, cetyldimethyl Carboxymethyl betaine, cocamidopropyl betaine, etc. are mentioned.
  • the nonionic surfactant may be alkanol amide or amine oxide, and specific examples thereof include lauryl diethyl amine oxide, palm oil alkyldimethyl amine oxide, lauric acid diethanolamide, palm oil fatty acid diethanolamide, palm oil fatty acid monoethanol Amides and the like.
  • the preservative is at least one selected from the group consisting of methyl paraoxybenzoate, propyl paraoxybenzoate, sodium benzoate, methylchloroisothiazolinone, methylisothiazolinone and sodium benzoate. .
  • the viscosity modifier is any one or more consisting of cocamide M (CME), cocamide die (CDE) and sodium chloride.
  • the pH adjusting agent is any one or more consisting of sodium phosphate, disodium phosphate, citric acid and sodium citrate.
  • the hair conditioning agent is a dimethicone base, a cationic polymer or a combination thereof.
  • the hair conditioning agent may further include any one or more of tertiary amidoamine, quaternary ammonium compound, high melting point compound and silicon compound.
  • tertiary amidoamine examples include cocaamidopropyl dimethylamine, stearamidopropyl dimethylamine, beheniramidopropyl dimethylamine, oleamidopropyl dimethylamine, isostearamidopropyl dimethylamine, and the like. Can be.
  • quaternary ammonium compound examples include alkyl (14 to 22 carbon atoms) trimethyl ammonium chloride, dialkyl (14 to 22 carbon atoms) dimethyl ammonium chloride, hydrogenated tallow alkyl trimethyl ammonium chloride and ditallow alkyl dimethyl ammonium chloride. have.
  • high melting point compound examples include fatty alcohols, fatty acids, fatty alcohol derivatives, hydrocarbons, and the like, and more specifically, cetyl alcohol, stearyl alcohol, and cetostearyl alcohol.
  • silicone compound examples include polyalkylsiloxane, polyarylsiloxane, polyalkylarylsiloxane, and polyethersiloxane copolymers.
  • NIH3T3 cell line (Korea Cell Line Bank) was used as a cell line for the untreated, positive control, ginsenoside Rb1, ginsenoside Rb2, ginsenoside Rc, ginsenoside Rd, ginsenoside Re and ginsenoside Rg1 treatment groups. Three wells (DMEM, 10% FBS, 1% P / S) in each group was incubated.
  • BMP4 Inducer a trademark GIPCO of Thermo Fisher SCEINTIFIC
  • GIPCO trademark GIPCO of Thermo Fisher SCEINTIFIC
  • ginsenosides (Sigma) corresponding to ginsenoside Rb1, ginsenoside Rb2, ginsenoside Rc, ginsenoside Rd, ginsenoside Re and ginsenoside Rg1 treatment groups, respectively, except for the untreated group and the positive control group.
  • -Aldrich was prepared in stock at a concentration of 10 mM, and then diluted in the medium, and the treated medium was removed from the well of each treatment group at a concentration of 0.1 ⁇ M.
  • luciferase is expressed that can detect when a signal that WIF-1 expression occurs inside the cell arrives.
  • the substrate was treated with light, which was measured using a luminometer.
  • the control vector is inserted together to normalize the vector insertion amount of each cell, and alkaline phosphatase is expressed as a control gene, and this is also quantified by measuring the amount of light with a luminometer.
  • WIF-1 expression and control gene expression in each well were calculated as a ratio to determine the increase or decrease in WIF-1 expression relative to the control gene.
  • the group treated with ginsenoside Re and ginsenoside Rg 1 has a lower WIF-1 expression than other ginsenoside treated groups, and is less than the untreated group without any treatment. It can be confirmed that the amount of WIF-1 expression is low.
  • ginsenoside Re and ginsenoside Rg1 treated groups were used as melan-a cells (ATCC), a murine melanocyte cell line. Seeding to 1.5 X 10 4 cells / well in a 48 well plate and incubated for 24 hours at conditions of 10% CO 2 , 37 °C.
  • ginsenoside Re and ginsenoside Rg1 treatment groups 100 mg / ml BMP4 protein and 10 ⁇ M of the corresponding ginsenosides (Sigma-Aldrich) were treated in the ginsenoside Re and ginsenoside Rg1 treatment groups, respectively, except for the untreated and negative controls.
  • the ginsenoside Re and ginsenoside Rg1 treated groups were treated with the same concentrations, respectively, and further cultured for 72 hours.
  • the untreated group, negative control group, ginsenoside Re and ginsenoside Rg1 treated groups were washed with DPBS (Dulbecco's Phosphate-Buffered Saline), respectively. Then, 2 N NaOH (10% DMSO) was added to all groups, and the cells were lysed at 60 ° C. for 1 hour, and then cell lysates were transferred to 96-well plates, and the absorbance was measured at 475 nm. It was.
  • DPBS Dynabecco's Phosphate-Buffered Saline
  • the measured values were then calculated from the standard curve for synthetic melanin as melanin content.
  • the calculated melanin content was normalized to the total protein of each experimental group, and then the efficacy was evaluated by comparing the relative value with the control group. The results are shown in Table 4 and FIG. 3.
  • Test group Relative melanin synthesis amount (%) Standard Deviation No treatment group 100 5.3 Negative control 76.4 4.6 Ginsenoside treatment group Re 103.1 4.9 Rg1 107.5 6.1
  • the ginsenoside Rg1 and Re treatment group can be seen to show melanin production promoting efficacy in melanin forming cells inhibited melanin synthesis due to WIF-1.
  • WIF-1 which inhibits the Wnt signal, which is one of the melanin synthesis signals, inhibits the synthesis of melanin, thereby generating white hair, and when combined with the results of Table 4 and FIG. 3 and the results of Example 2, Ginseno The side Re and Rg1 inhibits the expression of WIF-1 and normalizes the melanin synthesis signal, confirming that melanin is synthesized. Through these results, the group treated with ginsenosides Re and Rg1 provides excellent anti-white hair. Can be.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention concerne une composition de prévention du grisonnement des cheveux, contenant du ginsénoside représenté par la formule chimique 1 en tant que principe actif (dans la formule chimique 1, R1 est un atome d'hydrogène, R2 est -O-glc ou -O-glc(2-1) rha, et R3 est-glc).
PCT/KR2016/010825 2015-09-30 2016-09-27 Composition de prévention du grisonnement des cheveux WO2017057891A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN201680057138.2A CN108135822A (zh) 2015-09-30 2016-09-27 用于防止白发的组合物
JP2018516107A JP2018529712A (ja) 2015-09-30 2016-09-27 白髪防止用組成物
KR1020160124524A KR102586261B1 (ko) 2015-09-30 2016-09-28 백모 방지용 조성물
HK18108371.2A HK1248569A1 (zh) 2015-09-30 2018-06-28 用於防止白髮的組合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2015-0137839 2015-09-30
KR20150137839 2015-09-30

Publications (1)

Publication Number Publication Date
WO2017057891A1 true WO2017057891A1 (fr) 2017-04-06

Family

ID=58427796

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/010825 WO2017057891A1 (fr) 2015-09-30 2016-09-27 Composition de prévention du grisonnement des cheveux

Country Status (5)

Country Link
JP (1) JP2018529712A (fr)
KR (1) KR102586261B1 (fr)
CN (1) CN108135822A (fr)
HK (1) HK1248569A1 (fr)
WO (1) WO2017057891A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019210245A (ja) * 2018-06-05 2019-12-12 日本メナード化粧品株式会社 Ｃｘｃｌ１２発現促進剤

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040101503A1 (en) * 2002-09-06 2004-05-27 Societe L'oreal S.A. Use of protectin activator to enhance the skin's resistance, composition comprising such activators and selection method
US20070009474A1 (en) * 2005-07-08 2007-01-11 The Procter & Gamble Company Personal care compositions and methods for the beautification of mammalian skin and hair
KR20120068148A (ko) * 2010-12-17 2012-06-27 계명대학교 산학협력단 회화나무 추출물을 유효성분으로 포함하는 백반증 또는 백모 개선용 조성물
KR101343819B1 (ko) * 2013-04-05 2013-12-20 대동고려삼 주식회사 11종의 진세노사이드 성분을 유효성분으로 하는 홍삼농축액 분말, 비타민 및 미네랄로 조성된 항스트레스, 항고지혈증 및 항비만용 조성물 및 건강기능식품
KR20140126892A (ko) * 2013-04-24 2014-11-03 (주)아모레퍼시픽 진세노사이드 Rg3를 함유하는 피부 외용제 조성물
KR20150007975A (ko) * 2013-07-11 2015-01-21 (주)아모레퍼시픽 발모 및 육모 촉진용 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63198609A (ja) * 1987-02-14 1988-08-17 Eikoudou:Kk 化粧料

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040101503A1 (en) * 2002-09-06 2004-05-27 Societe L'oreal S.A. Use of protectin activator to enhance the skin's resistance, composition comprising such activators and selection method
US20070009474A1 (en) * 2005-07-08 2007-01-11 The Procter & Gamble Company Personal care compositions and methods for the beautification of mammalian skin and hair
KR20120068148A (ko) * 2010-12-17 2012-06-27 계명대학교 산학협력단 회화나무 추출물을 유효성분으로 포함하는 백반증 또는 백모 개선용 조성물
KR101343819B1 (ko) * 2013-04-05 2013-12-20 대동고려삼 주식회사 11종의 진세노사이드 성분을 유효성분으로 하는 홍삼농축액 분말, 비타민 및 미네랄로 조성된 항스트레스, 항고지혈증 및 항비만용 조성물 및 건강기능식품
KR20140126892A (ko) * 2013-04-24 2014-11-03 (주)아모레퍼시픽 진세노사이드 Rg3를 함유하는 피부 외용제 조성물
KR20150007975A (ko) * 2013-07-11 2015-01-21 (주)아모레퍼시픽 발모 및 육모 촉진용 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GAO, YAN ET AL.: "Anti-inflammatory Function of Ginsenoside Rgl on Alcoholic Hepatitis through Glucocorticoid Receptor Related Nuclear Factor-kappa B Pathway", JOURNAL OF ETHNOPHARMACOLOGY, vol. 173, 18 July 2015 (2015-07-18), pages 231 - 240, XP029286037 *
LIN, MAO ET AL.: "Ginsenosides Rb1 and Rg1 Stimulate Melanogenesis in Human Epidermal Melanocytes via PKA/CREB/MITF Signaling", EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, vol. 2014, 31 March 2014 (2014-03-31), pages 1 - 7, XP055385469 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019210245A (ja) * 2018-06-05 2019-12-12 日本メナード化粧品株式会社 Ｃｘｃｌ１２発現促進剤
JP7100351B2 (ja) 2018-06-05 2022-07-13 日本メナード化粧品株式会社 Ｃｘｃｌ１２発現促進剤

Also Published As

Publication number Publication date
KR20170038702A (ko) 2017-04-07
KR102586261B1 (ko) 2023-10-10
JP2018529712A (ja) 2018-10-11
HK1248569A1 (zh) 2018-10-19
CN108135822A (zh) 2018-06-08

Similar Documents

Publication Publication Date Title
WO2013027984A2 (fr) Composition cosmétique contenant un composant de thé vert
TW201519909A (zh) 含人參皂苷Ｒｇ３的皮膚外用劑組合物
KR102175249B1 (ko) 인삼 추출물과 녹차 추출물을 함유하는 모발 또는 두피 상태 개선용 조성물
KR101985356B1 (ko) 발효콩 추출물을 함유하는 피부 외용제 조성물
JP4027949B2 (ja) 養毛剤
WO2017057891A1 (fr) Composition de prévention du grisonnement des cheveux
CN107898656B (zh) 含有人参皂苷rf的皮肤外用剂组合物
KR20000022127A (ko) 두부용 조성물
KR20160119690A (ko) 니코틴산 아데닌 디뉴클레오티드 인산 및 그 유도체를 포함하는 발모 또는 육모 촉진제
WO2014189159A1 (fr) Composition comportant de l'extrait de pharbitis nil (l.) choisy pour empêcher la perte des cheveux et pour favoriser la croissance des cheveux
WO2021241780A1 (fr) Composition destinée à inhiber le grisonnement des cheveux, et son utilisation
WO2022019573A1 (fr) Composition pour prévenir la chute de cheveux ou favoriser la pousse de cheveux comprenant un extrait de la partie aérienne de carottes
JP3908245B2 (ja) 養毛剤
WO2022255799A1 (fr) Composition destinée à prévenir la chute des cheveux et à stimuler la pousse des cheveux, contenant gypsophila paniculata l.
KR102052517B1 (ko) 인삼 다당체와 녹차 다당체를 함유하는 모발 또는 두피 상태 개선용 조성물
WO2021157753A1 (fr) Composition pour prévenir la chute des cheveux et stimuler la repousse des cheveux
KR20150030924A (ko) 가공한 인삼 및 녹차에서 추출한 다당체를 함유하는 모발 또는 두피 상태 개선용 조성물
WO2021182725A1 (fr) Utilisation de milieu conditionné pour soulager et prévenir la perte de cheveux contenant une concentration élevée de vésicules extracellulaires ayant une fonction améliorée
WO2021149853A1 (fr) Composition pour la prévention de la chute des cheveux ou la stimulation de la pousse des cheveux
CN107970251B (zh) 含有人参皂苷Mc的皮肤外用剂组合物
KR20160066169A (ko) 이카리시드 b2를 유효성분으로 함유하는 백모 방지용 및 백반증 개선용 조성물
KR20160068236A (ko) 파나세노시드를 함유하는 모발 또는 두피 상태 개선용 조성물
KR20160066254A (ko) 피크리오노시드 a를 함유하는 모발 또는 두피 상태 개선용 조성물
KR20160066251A (ko) 이카리시드 b2를 함유하는 모발 또는 두피 상태 개선용 조성물
KR20160068233A (ko) (-)-유데스민을 함유하는 모발 또는 두피 상태 개선용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16852037

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2018516107

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16852037

Country of ref document: EP

Kind code of ref document: A1